SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following the appointment of a new COO with deep semiconductor manufacturing expertise, signaling a strategic shift toward scaling high-volume production for AI data center infrastructure. The community is actively discussing the stock's resilience amid broader market volatility, with significant debate focused on the company's massive options volume and the potential for a gamma squeeze as investors bet on future hyperscaler adoption.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors weigh significant volatility and heavy speculation ahead of the company's upcoming earnings report. The community is actively debating the impact of recent government contract wins, potential institutional interest, and broader space sector momentum driven by the anticipation of a major SpaceX IPO.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors aggressively position themselves ahead of the upcoming first-quarter earnings report, which will be released before the bell on May 14. The community is actively debating the stock's future, balancing optimistic sentiment about revenue growth and recent institutional accumulation against concerns over dilution and persistent share price volatility.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is experiencing heightened investor interest as the community weighs recent institutional call buying and potential reversal indicators against ongoing concerns regarding housing market headwinds and consumer spending. Traders are actively debating whether the stock is finding a bottom ahead of its upcoming earnings report or if macroeconomic pressures will continue to weigh on the retail sector.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is generating significant community buzz as retail investors debate its potential for a short squeeze amid high short interest and recent heavy insider buying. The conversation remains split between those focused on the company's long-term growth and partnerships and those concerned about volatility and macroeconomic pressures.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is currently trending as a prominent AI infrastructure play, driven by a surge in hyperscaler demand and strong earnings results that have spurred a significant re-rating of the stock. The community is actively discussing the company's transformation, comparing its current momentum to historical cycles and debating whether the recent rally signals long-term durability or excessive hype.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors celebrate the resignation of the FDA commissioner, an event widely viewed as a catalyst that could accelerate the regulatory review of Anktiva and remove long-standing barriers to market expansion. The community is actively discussing the stock's potential for a short squeeze and long-term institutional growth, with many members emphasizing that the shift in leadership finally aligns the regulatory environment with the company's mission to redefine cancer treatment.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors react to a significant leadership change following the departure of the CEO, while simultaneously digesting mixed quarterly results that highlighted both a revenue miss and optimism regarding the transition to U.S.-based manufacturing. The community is actively debating the company's valuation, questioning its heavy debt load, and speculating on potential future acquisition interest as the stock remains a high-interest target for short sellers.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is surging as community sentiment centers on a high-stakes diplomatic trip to China, with investors betting that CEO Jensen Huang will secure breakthroughs in chip export clearances. Traders are actively debating whether this momentum will trigger a short squeeze and sustain a breakout toward new milestones, while others remain focused on the broader AI infrastructure supercycle despite conflicting macroeconomic signals.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing increased attention as the community focuses on upcoming clinical readouts and legislative developments, such as the Kidney Care Access Protection Act, which investors believe could improve reimbursement for DefenCath. Market discussions are dominated by institutional holding shifts, speculation regarding the upcoming earnings report, and ongoing debates over how the company's product adoption within dialysis networks will impact the stock's path to future profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AVLN Allocated in Avalyn at the $18.00 IPO pricing yesterday. Tape ran as high as $30.20 on the debut and is currently churning in the upper $20&#39;s. I&#39;m holding this one... not a flip. I don&#39;t like selling immediately after an allocation. It&#39;s bad form professionally, but more importantly, I think the upside here--longer-term--is substantially larger than a day-one pop. 
 
Why this one matters to me: 
The Esbriet story. InterMune built pirfenidone into the dominant IPF therapy, Roche paid $8.3 billion in cash to acquire the company at a 63% premium to the unaffected price, and it became one of my best biotech trades of the last decade. AP01 is an inhaled formulation of the same molecule -- pirfenidone -- designed to deliver the drug directly to the lungs, enhance local efficacy, and reduce the systemic side effects that limit dosing on the oral version. The science is sound and the unmet need is real. 
 
What bolsters my conviction further: 
Frank Salisbury, who led the U.S. launch and served as National Head of Sales for Esbriet at InterMune /Genentech, just joined Avalyn as SVP of Commercial. Having someone from the original pirfenidone commercialization team -- someone who saw that molecule through to a multi-billion-dollar exit -- now running commercial strategy for the inhaled version is the kind of pedigree detail that the market doesn&#39;t price in early enough. 
 
Catalysts ahead: 
Phase 2b (MIST) data for AP01 in progressive pulmonary fibrosis and the Phase 2 (AURA-IPF) readout for AP02, which is an inhaled formulation of nintedanib. Both are significant de-risking events. Expect the usual post-IPO chop to continue until the options chain opens up, likely early next week. 
 
For those who follow me for biotech, I&#39;d wait for this to come in before initiating. But read the S-1. The inhaled delivery platform, the management pedigree, and the pipeline optionality make this one worth understanding now, not after the data drops. 
 
Positioned for the long haul. 
 
Not financial or trading advice... just sharing what I own and why. DYOR.

StockTwits Web

Avalyn Pharma Inc.

 Allocated in Avalyn at the $18.00 IPO pricing yesterday. Tape ran as high as $30.20 on the debut and is currently churning in the upper $20's. I'm holding this one... not a flip. I don't like selling immediately after an allocation. It's bad form professionally, but more importantly, I think the upside here--longer-term--is substantially larger than a day-one pop. 
 
Why this one matters to me: 
The Esbriet story. InterMune built pirfenidone into the dominant IPF therapy, Roche paid $8.3 billion in cash to acquire the company at a 63% premium to the unaffected price, and it became one of my best biotech trades of the last decade. AP01 is an inhaled formulation of the same molecule -- pirfenidone -- designed to deliver the drug directly to the lungs, enhance local efficacy, and reduce the systemic side effects that limit dosing on the oral version. The science is sound and the unmet need is real. 
 
What bolsters my conviction further: 
Frank Salisbury, who led the U.S. launch and served as National Head of Sales for Esbriet at InterMune /Genentech, just joined Avalyn as SVP of Commercial. Having someone from the original pirfenidone commercialization team -- someone who saw that molecule through to a multi-billion-dollar exit -- now running commercial strategy for the inhaled version is the kind of pedigree detail that the market doesn't price in early enough. 
 
Catalysts ahead: 
Phase 2b (MIST) data for AP01 in progressive pulmonary fibrosis and the Phase 2 (AURA-IPF) readout for AP02, which is an inhaled formulation of nintedanib. Both are significant de-risking events. Expect the usual post-IPO chop to continue until the options chain opens up, likely early next week. 
 
For those who follow me for biotech, I'd wait for this to come in before initiating. But read the S-1. The inhaled delivery platform, the management pedigree, and the pipeline optionality make this one worth understanding now, not after the data drops. 
 
Positioned for the long haul. 
 
Not financial or trading advice... just sharing what I own and why. DYOR.